Navigation Links
IntegriChain Appoints John Bailye to Its Board of Directors
Date:6/2/2008

PRINCETON, N.J., June 2 /PRNewswire/ -- IntegriChain, Inc. today announced the appointment of industry veteran John Bailye to the Company's Board of Directors, further bolstering its position as a leader in the pharmaceutical information services industry.

Mr. Bailye, 54, recently retired from his position as Chairman & CEO of Dendrite International after Dendrite was acquired by French information provider Cegedim. Under Mr. Bailye's leadership, Dendrite, a pharmaceutical sales force automation system company, grew to more than 3500 employees, acquired 23 companies and generated $450 million in global sales revenue to become the leading SFA tool in the pharmaceutical industry. Throughout his career, Mr. Bailye has served on a number of not-for-profit organizations, including the New Jersey Technology Council where he was co-Founder and Board Member. Currently, Mr. Bailye is also a director, advisor and investor in Solar Centre LLC, a General Partner of the Roxiticus Life Sciences Fund.

Kevin Leininger, Chief Executive Officer of IntegriChain commented, "We are thrilled to have John join our Board of Directors. John is a seasoned executive and leader who brings a wealth of experience and proven track record in building a strong information services company in the pharmaceutical industry."

"IntegriChain has an innovative approach to helping pharmaceutical companies take more advantage of their channel data for commercial applications such as forecasting, demand validation and product launch," said Mr. Bailye. "I am excited by the sizeable potential IntegriChain represents and I look forward to leveraging my experience to help the Company expand its possibilities even further."

About IntegriChain

IntegriChain, Inc. is an information services company which provides data collection, integration, enrichment, analysis and reporting of sales and inventory activity for the pharmaceutical industry. IntegriChain enables manufacturers to improve sales performance and increase patient safety by maximizing transparency and accountability in the supply chain. IntegriChain's Enriched Channel Sales(TM) and advanced analytics are transforming the role of channel data within key pharmaceutical application areas including new product launch, sales forecasting, and demand analysis.


'/>"/>
SOURCE IntegriChain, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Trius Appoints Paul Truex to Board of Directors
2. Pelikan Technologies Appoints Denny Ware to Board of Directors
3. MAP Pharmaceuticals Appoints Marco Rosa Vice President of Human Resources
4. Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board
5. Nventa Appoints Gordon H. Busenbark to Board of Directors
6. Schering-Plough Appoints Janet M. Barth Vice President, Investor Relations
7. Informed Medical Communications Appoints New Chief Financial Officer
8. Orchid Cellmark Appoints Jeffrey S. Boschwitz as Vice President, North America Marketing & Sales
9. WuXi PharmaTech (NYSE: WX) Appoints Dr. Peng Wang as VP of Discovery Biology
10. Takedas Antibody Therapeutics Research Company, Takeda San Francisco, Inc. Appoints Mary Haak-Frendscho, Ph.D. as President and CSO
11. VentiRx Pharmaceuticals Appoints Dr. Elliott Grossbard to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... Belgium (PRWEB) , ... February 16, 2017 , ... ... (SIOTAD) framework primarily aimed at the agricultural industry. Pilot studies are about to get ... products through IoT, Big Data and 5G innovations. The concept is expected to be ...
(Date:2/16/2017)... 16, 2017  MDNA Life Sciences Inc. (MDNA), ... liquid biopsy tests based on the mitochondrial genome, ... license agreement with its first international commercial partner, ... test for prostate cancer, the Prostate Mitomic Test ... This is the first overseas appointment for MDNA ...
(Date:2/16/2017)... --  Biostage, Inc. (Nasdaq: BSTG ), ... organ implants to treat cancers and other life-threatening conditions ... closing on February 15, 2017 of its previously announced ... warrants to purchase 20,000,000 shares of common stock, for ... priced at $0.40 per share of common stock, with ...
(Date:2/16/2017)... , Feb. 16, 2017  Champions Oncology, Inc. (NASDAQ: ... development and sale of advanced technology solutions and products ... today announced the addition of new cohorts of PDX ... new models will expand Champions, product line in hepatocellular ... neck cancer, AML, and non-small cell lung cancer (including ...
Breaking Biology Technology:
(Date:2/3/2017)... 3, 2017  Texas Biomedical Research Institute announced that its ... Schlesinger as the Institute,s new President and CEO. Dr. ... 31, 2017. He is currently the Chair of the Department ... for Microbial Interface Biology at Ohio State University. ... President and CEO of Texas Biomed," said Dr. James ...
(Date:2/2/2017)... 2017   TapImmune, Inc. (NASDAQ: ... in the development of innovative peptide and gene-based ... and metastatic disease, announced today it has successfully ... a second clinical lot of TPIV 200, the ... The manufactured vaccine product will be used to ...
(Date:2/2/2017)... 1, 2017  Central to its deep commitment ... worldwide, The Japan Prize Foundation today announced the ... pushed the envelope in their respective fields of ... scientists are being recognized with the 2017 Japan ... only contribute to the advancement of science and ...
Breaking Biology News(10 mins):